Use of other investigational drugs at the time of screening or within the last  days.
Subjects may not receive any other concomitant investigational agents
Concomitant use of any anticancer therapy or use of any investigational agent(s).
Concomitant use of other cytotoxic or cytostatic drugs other than PTX
Concomitant use of other investigational agents.
Use of any investigational drugs within  days prior to dosing
Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.
Concomitant use of other investigational agents
Use of other investigational drugs
Concomitant use of any other investigational drugs
Concomitant use of any other investigational or anticancer agent(s).
Concomitant use of other investigational agents
Prior use of investigational drugs =<  days prior to registration
Concomitant use of any other investigational drugs
Concomitant use of any other investigational drugs
Subjects may not receive any other concomitant investigational agents
Subjects receiving concomitant treatment with radiotherapy or other investigational drugs
Concomitant use of any other investigational drugs
Use of other investigational drugs
Serious uncontrolled concomitant disease that would contraindicate the use of any of the investigational drugs used in this study or would put the participants at high risk for treatment-related complications
Use of anti-cancer treatment (including investigational drugs) within  days
Use of investigational drugs within  weeks of signing consent or foreseen use during the study
Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug [IND] for initial efficacy investigations)
Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug (IND) for initial efficacy investigations
Concomitant investigational therapy
Concomitant investigational therapy
